

Attorney Docket No.: **ISIS-5028**  
Serial No.: **10/080,979**  
Page 5

## REMARKS

The Applicants thank the Examiner and her Supervisor for their time and courtesy during the personal interview at the US Patent and Trademark Office on April 18, 2005.

Claims 1-16 are pending in the case. Claim 8 is objected to for being in improper dependent form. Claims 1, 2, 5-8 and 11-16 are rejected under 35 USC 112, first paragraph for failing to comply with the enablement requirement. Claims 3, 4, 9 and 10 are objected to as being dependent on rejected claims. Claims 1-11 are rejected under the judicially created doctrine of obviousness type double patenting. Claims 1, 6 and 12 are amended. The amendments are supported on page 122, lines 6-9. Claims 2, 8, and 13 are cancelled.

The Applicants have amended the claims as set forth above and submit that in view of the forgoing amendments and following arguments that the claims are now in a proper form for allowance.

### I. Claim rejections under 35 USC 112, paragraph 1

The Examiner has rejected claims 1, 2, 5-8 and 11-16 under 35 USC 112, paragraph 1 for failing to meet the enablement requirement. Claims 3-4 and 9-10 are not included in the rejection; therefore, they must be enabled by the specification.

Claims 3-4 and 9-10 include the limitations that either one or both of the sterol moieties be cholesterol. The Applicants submit that the properties of sterols are well known to those skilled in the art. Moreover, it has been demonstrated that the addition of any of a number of sterol moieties to an oligonucleotide has substantially the same effect on the melting temperature of the oligonucleotide to its complement as shown in Table 2 on page 319 of *Antisense Research and Applications* (Eds. ST Crooke and B Lebleu, 1993, copy enclosed). As antisense oligonucleotides function by hybridizing to their target sequence and modification of an oligonucleotide with a sterol moiety does not

Attorney Docket No.: **ISIS-5028**  
Serial No.: **10/080,979**  
Page 6

interfere with this binding, one would have a reasonable expectation that an oligonucleotide modified with cholesterol moieties would function similarly to an oligonucleotide modified with other sterol moieties (e.g. digoxigenin, cholic acid). Therefore the rejection under 35 USC 112, paragraph 1 for lack of enablement of claims 1, 2 and 5-7 is traversed.

The Examiner points to the Letsinger reference to demonstrate the unpredictable nature of oligonucleotides in the inhibition of gene expression and the treatment of disease. The Applicants submit that the claims of the instant application are drawn to the use of antisense oligonucleotides. It is unlikely that the oligonucleotides of Letsinger are functioning by an antisense mechanism as stated in the final sentence of the abstract which states, "There facts, and the finding that the activity of the phosphorothioate decamers does not correlate with specific sequence, suggests that a mechanism other than "antisense inhibition" may be operative in this system." Per the statements of Letsinger, the teachings of the reference are not relevant to the claims of the instant application.

A number of sterol conjugated antisense oligonucleotides have been demonstrated to function in both *in vitro* and *in vivo* assays as reviewed in *Antisense Drug Technology* (Ed. ST Crooke, 2001, pp. 394-407 copy enclosed). A number of different targets are discussed including ICAM, ras, raf, PKC-alpha, CYP2B1, HCMV, p75 and HIV-1. The Applicants submit that these data support the broad use of cholesterol conjugated antisense oligonucleotides as claimed in the instant invention.

## **II. Double patenting rejection**

The Examiner has rejected claims 1-11 for obviousness-type double patenting over claim 2 of US Patent No 6,753,423. The Applicants submit that the rate of clearance of the oligonucleotide containing two modifications is not obvious in view of claim 2 of the '423 patent. Therefore the rejection is traversed.

**RECEIVED  
CENTRAL FAX CENTER**

Attorney Docket No.: **ISIS-5028**  
Serial No.: **10/080,979**  
Page 7

**JUL 11 2005**

The second double patenting rejection in view of US Patent Application 2004/0142899 is a provisional double patenting rejection. The Applicants request that this rejection be held in abeyance until allowable matter is identified in one of the cases.

### **III. Fees**


The Applicants hereby request that the Commissioner charge Deposit Account No. 50-0252 the fee of \$225.00 for an extension in time of reply of two (2) months, small entity. It is believed that no further fee is due. However, if an additional fee is due, the Commissioner is hereby entitled to charge the fee to the Deposit Account listed above citing Reference No. ISIS-5028.

### **IV. Conclusion**

Applicants believe that the foregoing comprises a full and complete response to the Office Action of record. Accordingly, an early office action on the merits of the case is respectfully requested.

Respectfully submitted,

Date: July 11, 2005

  
Colleen J. McKiernan, PhD  
Registration No. 48,570

Isis Pharmaceuticals  
1896 Rutherford Road  
Carlsbad, CA 92008

Phone: 760-603-2722  
Facsimile: 760-603-3820

Enclosures: 2 references, 14 pages total

**BEST AVAILABLE COPY**

# **Antisense Research and Applications**

Edited by

**Stanley T. Crooke, M.D., Ph.D.**

ISIS Pharmaceuticals  
Carlsbad, California

**Bernard Lebleu, Ph.D.**

Laboratoire Biochimie des Proteines  
Universite Montpellier II  
Montpellier, France



**CRC Press**

**Boca Raton Ann Arbor London Tokyo**

**Library of Congress Cataloging-in-Publication Data**

Antisense research and applications/edited by Stanley T. Crooke,  
Bernard Lebleu.

p. cm.

Includes bibliographical references and index.

ISBN 0-8493-4705-X

1. Antisense nucleic acids—Therapeutic use. I. Crooke,  
Stanley T. II. Lebleu, Bernard.

RM666.A564A58 1993

615'.31--dc20

92-35004  
CIP

This book represents information obtained from authentic and highly regarded sources. Reprinted material is quoted with permission, and sources are indicated. A wide variety of references are listed. Every reasonable effort has been made to give reliable data and information, but the author and the publisher cannot assume responsibility for the validity of all materials or for the consequences of their use.

Neither this book nor any part may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, microfilming, and recording, or by any information storage and retrieval system, without permission in writing from the publisher.

All rights reserved. Authorization to photocopy items for internal or personal use, or the personal or internal use of specific clients, is granted by CRC Press, Inc., provided that \$.50 per page photocopied is paid directly to Copyright Clearance Center, 27 Congress Street, Salem, MA 01970 USA. The fee code for users of the Transactional Reporting Service is ISBN 0-8493-4705-X/93 \$0.00 + \$.50. The fee is subject to change without notice. For organizations that have been granted a photocopy license by the CCC, a separate system of payment has been arranged.

The copyright owner's consent does not extend to copying for general distribution, for promotion, for creating new works, or for resale. Specific permission must be obtained from CRC Press for such copying.

Direct all inquiries to CRC Press, Inc., 2000 Corporate Blvd., N.W., Boca Raton, Florida 33431.

© 1993 by CRC Press, Inc.

International Standard Book Number 0-8493-4705-X

Library of Congress Card Number 92-35004


Printed in the United States of America 1 2 3 4 5 6 7 8 9 0

Printed on acid-free paper

lications

## Designer Antisense Oligonucleotides

317



SCHEME 9. The ISIS 2'-aminolinker.

## III. SUGAR MODIFICATIONS

As discussed in Section II, in post-oligonucleotide synthesis, a nucleophile such as an amino group with an appropriate linker can be introduced at the 3' or 5' end of the oligonucleotide, at the 5-position of uracil, N<sup>4</sup> position of cytosine, and N<sup>6</sup>, N<sup>2</sup> positions of purine, as well as in the phosphodiester backbone. Each of these approaches, however, has limitations. The terminal linkers place the functional groups at the ends and thus limit recognition of a given site within the double helix. Linkers attached to the bases may interfere with base pairing and/or stacking interactions, and linkers attached to the backbone present chirality problems. At ISIS Pharmaceuticals we have developed conjugation chemistry suitable for both DNA and RNA modifications that is based on an aminolinker (2'-O-pentylamine) attached to the 2'-O-position of the sugar.

## A. CONJUGATION AT THE 2' POSITION

## 1. Chemistry

The chemistry for constructing a phosphoramidite monomer with a 2'-aminolinker is based on alkylation reactions of adenosine developed by Guinosso and Cook.<sup>31</sup> The monomer, which is designed for automated DNA synthesis, is produced by alkylation of the anion resulting from NaH/DMF treatment of adenosine at 0 to 5°C with N-(5-bromopentyl)phthalimide base protection with benzoyl chloride employing transient protection of 5'- and 3'-hydroxyls followed by tritylation and phosphitylation to obtain the desired phosphoramidite.

Using this 2'-aminolinker, we have conjugated various molecules<sup>32</sup> to oligonucleotides: (1) cholic acid, for uptake enhancement; (2) digoxigenin, a steroidal molecule that has hydrophobic properties that enhance uptake, and it is also a reporter molecule in a commercially available detection system; (3) biotin; (4) fluorescein, which are reported molecules to study uptake; (5) pyrene; (6) acridine intercalators; (7) aryl azides which are photoactivatable crosslinking agents; and (8) polyamines such as spermine and pentaethylenhexamine for uptake studies and also as potential cleaving molecules.

Shown below are the oligodeoxynucleotides I and II, which incorporate the 2'-O-modified adenosine (indicated as A\*). The sequence belongs to the E2 region of the bovine papilloma virus-1 (BPV-1) and has demonstrated an antisense effect. The nucleoside compositions of I and II were established by HPLC analysis after the oligonucleosides had been cleaved by snake venom phosphodiesterase and calf-thymus alkaline phosphatase.

I: 5'-CTGTCTCCA\*TCCTCTTCACT3'  
BPV sequence, single-site labeling


II: 5'-CTGTCTCCA\*TCCTCTTCA\*CT3'  
BPV, double-site labeling

oxyne-  
oligo-  
a basic  
- at the  
Oligo);  
that has  
cleotide

enerate  
l-O-po-  
2.0 to  
l group

l phos-  
wever,  
at was

duplex  
trature  
results  
te that  
gation



SCHEME 10. Conjugations at the 2' position.

Oligonucleotides I and II were reacted with the compounds summarized in Scheme 10, each of which had a functional group reactive to an amino group. Each of the functionalities mentioned above was conjugated to the oligomers. The conjugation reactions were carried out in an aqueous buffer at pH 8 to 9 under standard conditions. The conjugation yields varied between 70 and 90%. This approach facilitates multiple conjugation; a product with multiple labels could be synthesized and purified by HPLC. In addition, we have synthesized oligonucleotides containing a phosphorothioate backbone and RNA analogs with 2'-OMe groups that incorporate our 2'-aminolinker at a specific site. These derivatives are already known to have either nuclease stability (thioates) or enhanced hybridization properties (2'-OMe derivatives). Conjugations to the 2'-aminolinker were carried out from thioates and RNA mimics as well. The 2'-aminolinker provides an additional handle for conjugating other functionalities, such as lipophilic groups to improve membrane transport properties or nucleic acid cleaving agents.

## 2. Biophysical Studies

### a. Thermal Melt Analysis

First, the effect of the 2'-aminolinker alone was studied;<sup>23</sup> a 17-mer oligonucleotide (GGA\*CCGGA\*A\*GGTA\*CGA\*G) incorporating five 2'-O-aminopentoxymodifications was synthesized and purified. On melting against DNA, a net destabilization of 6.1°C was observed which averages to -1.2°C/modification. Against RNA, at the same time, a net stabilization of 1.1°C was noted which translates to 0.22°C stabilization/modification. Similarly the ISIS 1570 oligonucleotide phosphorothioate (TGGGA\*GCCA\*TA\*CGA\*GGC)

**TABLE 2**  
**Duplex Melting Temperature of the 2'-**  
**Conjugates of the BPV Oligonucleotide**  
**(Against DNA)**

I: 5'-CTG TCT CCA\*TCC TCT TCA CT-3'  
 II: 5'-CTG TCT CCA\*TCC TCT TCA\*CT-3'  
 III: 5'-CTG TCT CCA TCC TCT TCA CT-3'

Oligo	Modification	$T_m$ , °C <sup>a</sup>	$\Delta T_m/\text{mod}^b$
III	Wild type	60.5	—
I	2'-O-Pentyl-NH <sub>2</sub> (1 mod)	58.1	—
IB	Biotin conjugate	56.4	-1.7
IC	Cholic acid conjugate	55.5	-2.6
ID	Digoxigenin conjugate	55.8	-2.3
IF	Fluorescein conjugate	55.1	-3.0
IP	Pyrene conjugate	62.6	+4.5
IA	Acridine conjugate	58.6	+0.5
II	2'-O-Pentyl-NH <sub>2</sub> (2 mod)	56.9	—
IIB	Biotin conjugate	54.4	-1.3
IIC	Cholic acid conjugate	54.3	-1.3
IID	Digoxigenin conjugate	53.8	-1.6
IIF	Fluorescein conjugate	53.4	-1.8
IIP	Pyrene conjugate	65.1	+4.1
IIA	Acridine conjugate	58.1	+1.2

<sup>a</sup>  $T_m$  buffer used ~ 100 mM NaCl, 10 mM Na<sub>2</sub>PO<sub>4</sub>, 0.1 mM EDTA, pH 7.0.

<sup>b</sup> Compared to the modified Oligo I or II as appropriate.

was synthesized replacing all four adenosines with the aminolinker containing adenosine. The resultant 18-mer oligonucleotide had the same  $T_m$  as the parent thioate against the RNA complementary strand. Thus, in antisense applications, a 2'-aminolinker does not affect duplex hybridization and even offers some small stabilization.

Second, the conjugates from oligonucleotides I and II were studied (Table 2). In thermal melting studies<sup>94</sup> against complementary DNA, we have observed nearly 2 to 3°C destabilization for substituents like biotin, fluorescein, digoxigenin, and cholic acid. Even large steroidal molecules exhibit only modest destabilization. The destabilization observed is less pronounced than for the base and backbone modifications mentioned earlier. Furthermore, the destabilizing effects are *not* additive:  $\Delta T_m/\text{modification}$  is less for doubly conjugated oligonucleotides than for singly modified oligonucleotides.

In the case of pyrene and acridine conjugates, enhanced duplex stability has been observed. The stabilization was significant in pyrene conjugates (4°C/modification) and marginal in the case of acridine conjugates (0.5 to 1°C/modification), although this difference may be due to different lengths of the groups involved between acridine and the aminolinker used vs. pyrene and the aminolinker (longer linker in the second case). We are pursuing NMR and other spectroscopic (fluorescence quenching) studies to confirm intercalation of these ligands in duplexes.

In the cases of pyrene and fluorescein modifications in single strand oligodeoxynucleotides, fluorescence properties were found to be additive; in single strand conjugates like the one derived from oligonucleotide II shown above, there was no fluorescence quenching of one chromophore by the other.

cheme 10, each  
functionalities  
ns were carried  
njugation yields  
; a product with  
ave synthesized  
gs with 2'-OMe  
ives are already  
ation properties  
rom thioates and  
for conjugating  
ort properties or

oligonucleotide  
ky modifications  
ion of 6.1°C was  
same time, a net  
odification. Sim-  
TA\*CGA\*GGC)



# Antisense Drug Technology

Principles, Strategies, and Applications

edited by  
**Stanley T. Crooke**  
*Isis Pharmaceuticals, Inc.*  
*Carlsbad, California*



MARCEL DEKKER, INC.

NEW YORK • BASEL

**ISBN: 0-8247-0566-1**

This book is printed on acid-free paper.

**Headquarters**

Marcel Dekker, Inc.  
270 Madison Avenue, New York, NY 10016  
tel: 212-696-9000; fax: 212-685-4540

**Eastern Hemisphere Distribution**

Marcel Dekker AG  
Hutgasse 4, Postfach 812, CH-4001 Basel, Switzerland  
tel: 41-61-261-8482; fax: 41-61-261-8896

**World Wide Web**

<http://www.dekker.com>

The publisher offers discounts on this book when ordered in bulk quantities. For more information, write to Special Sales/Professional Marketing at the headquarters address above.

**Copyright © 2001 by Marcel Dekker, Inc. All Rights Reserved.**


Neither this book nor any part may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, microfilming, and recording, or by any information storage and retrieval system, without permission in writing from the publisher.

Current printing (last digit):  
10 9 8 7 6 5 4 3 2 1


**PRINTED IN THE UNITED STATES OF AMERICA**

394


Manoharan




2'-deoxyoligonucleotide




2'-deoxyoligonucleotide phosphorothioate




2'-O-Me-2'-O-MeRNA



2'-O-Me-2'-O-MeRNA



2'-deoxyoligonucleotide methylphosphonate



PNA: Peptide Nucleic Acid

Figure 2 First-generation and second-generation chemistries to which ligands have been conjugated.

## Oligonucleotide Conjugates

395

phlicity dominates due to the extensive hydrogen bonding possible with the phosphate and sugar residues. This intrinsic hydrophilicity is augmented by the anionic nature of the backbone. The hydrophilic character and the anionic backbone of the drug reduces cellular permeation. Conjugation of lipophilic molecules is the obvious way to solve the cellular permeation problem.

Various lipophilic molecules have been conjugated to antisense oligonucleotides and Fig. 3 shows the structures of the compounds. Among them, cholesterol is perhaps the best characterized. It has been studied by various groups for the past 11 years (11) and has been reported to enhance binding of oligonucleotides to lipoproteins and, thereby, enhance cellular association and transport (12,13). The majority of this section will concentrate on the considerable data available on cholesterol-conjugated oligonucleotides. Data available on other lipophilic ligands will also be summarized.

## 2. Uridine-Conjugated Lipophilic Phosphoramidites and Solid Supports

Synthesis of 5'-O-dimethoxytrityl-2'-O-(6-aminohexyl)uridine and the 3'-isomer, 5'-O-dimethoxytrityl-3'-O-(6-aminohexyl)uridine, has been described by Manoharan et al. (14,15). Derivatization of these amines (Fig. 4) with cholesterol chloroformate yielded cholesterol carboxylate derivatives. Adamantane acetic acid, eicosanoic acid, and pyrene butyric acid were converted to their pentafluorophenol esters and condensed with these amines. 1,2-Di-O-hexadecyl-rac-glycerol was converted to the corresponding carbonate using disuccinimidyl carbonate. The carbonate was condensed with the amines to yield the modified nucleosides containing linkages. The nucleoside conjugates, after purification on a silica gel column, were phosphorylated to yield the corresponding phosphoramidites and then incorporated into oligomers. Each nucleoside was then condensed with long-chain alkylamino controlled pore glass (CPG).

## 3. Cholesterol-Conjugated ICAM-1 Antisense Oligonucleotides

An antisense oligonucleotide targeting the 3' untranslated region of mouse intercellular adhesion molecule-1 (ICAM-1) was used for characterization of lipophilic conjugates. ISIS-3082 (see Table I for oligonucleotide sequences), a phosphorothioate oligonucleotide, shows antisense inhibition in cell culture with an  $IC_{50}$  of 100 nM when formulated with a cationic lipid for delivery. Uridine nucleoside synthons containing cholesterol at the 2' or 3' position were synthesized and incorporated at the 5' end of the ISIS-3082 resulting in the oligonucleotide-cholesterol conjugate ISIS-8005 (14).

Cell culture experiments were used to evaluate the effect of ISIS-3082 and ISIS-8005 on ICAM-1 expression without any cationic lipid. ISIS-8005 inhibited ICAM-1 in a dose-dependent manner with an  $IC_{50}$  of 2.5  $\mu$ M, while ISIS-3082

397

## Oligonucleotide Conjugates




Figure 3 Continued

398

## Menoheran




Figure 3 Lipophilic molecules.

398

Manoharan




Figure 4 2'- and 3'-O-(6-aminohexyl) uridine derivatives.

did not show any activity, even when high concentrations of oligonucleotide were used. Furthermore, the inhibition of protein expression appears to be target specific. Neither molecule showed significant inhibition of VCAM-1 expression.

To understand the role of cholesterol in improving the function of ISIS-3082, we asked whether this molecule works merely because it is more hydrophobic than an unconjugated oligonucleotide or through specific protein-mediated (e.g., apo-E) binding and entry into cells. The answer was obtained by synthesizing and analyzing other lipophilic conjugates of ISIS-3082. Adamantane, pyrene, eicosenoic acid, and  $C_{16}$  glyceride lipid nucleoside conjugates were synthesized and incorporated into ISIS-3082 in the same fashion as cholesterol. Similar lipophilic molecules have been conjugated to oligonucleotide and studied in an HIV system (16).

A reverse-phase HPLC assay was used to measure the relative lipophilicity of these conjugates as a model for the interaction between the cell membrane and the antisense oligonucleotide. The retention time of the oligonucleotide (and

Table 1 ICAM-1 Oligonucleotides with Lipophilic Modifications

Compound	Composition
ISIS-3082	5'-Ts G s C s A s T s C s C s C s C s C s A s G s G s C s C s A s C s C s A s T
ISIS-9047	5'-T* s G s C s A s T s C s C s C s C s C s A s G s G s C s C s A s C s C s A s T (T* = 5'-octadecylaminoluridine)
ISIS-8005	5'-U* s G s C s A s T s C s C s C s C s C s A s G s G s C s C s A s C s C s A s T
ISIS-9388	(U* = 5'-2'-O-hexylamino-carbonyl-oxycholesterol)-uridine 5'-T s G s C s A s T s C s C s C s C s C s A s G s G s C s C s A s C s C s A s U* (U* = 5'-3'-O-hexylamino-carbonyl-oxycholesterol)-uridine

## Oligonucleotide Conjugates

399

presumably the lipophilicity) increases with the number of carbon atoms in the pendant group. There is a linear correlation between the percentage of acetonitrile needed for elution and the total number of carbons. The two compounds having the same number of carbons (pyrene and eicosenoic acid) elute at the same time, while the group having the greatest number of carbons (glyceride lipid) has the longest retention time. Thus a wide spectrum of lipophilicities was observed from the least lipophilic, unconjugated ISIS-3082, to the glyceride lipid conjugate, ISIS-11826. In the antisense efficacy assays, without any added cationic lipid formulation, relative order of lipophilicity was not reflected in efficacy. While the cholesterol conjugate does inhibit ICAM-1 expression, other conjugates failed to inhibit ICAM-1 expression within the concentration range of 1–10  $\mu$ M of oligonucleotides. The cholesterol-conjugated oligonucleotide shows a linear dose-dependent response in controlling the ICAM-1 expression. This experiment suggests that a receptor-mediated process may be operating in the case of cholesterol-conjugated oligonucleotides.

## 4. Pharmacokinetics of Cholesterol Conjugates and Other Lipophilic Conjugates

Biophysical and pharmacokinetic properties of lipophilic analogs of ISIS-3082 listed in Table 1 have been evaluated and reported (17). Compared to the parent compound, ISIS-3082, the three analogs (Fig. 5) with lipophilic conjugates, ISIS-9047 (5'-octadecylamine), ISIS-8005 [5'-(2'-O-hexylamino-carbonyl-oxycholesterol)], and ISIS-9388 [3'-(3'-O-hexylamino-carbonyl-oxycholesterol)] were more lipophilic than ISIS-3082 (three- and sevenfold, respectively, for the first two compounds as measured by reverse-phase HPLC retention times) but had similar binding affinity for complementary RNA (measured by thermal melting analysis,  $T_m$ ).

Tissue distribution and half-life in mice were analyzed using radioactively labeled phosphorothioate ISIS-3082 and cholesterol and  $C_{18}$  amine analogs. After bolus intravenous injection, the initial volumes of distribution of these more lipophilic phosphorothioate analogs, ISIS-9047 and ISIS-8005, were less and the initial clearance from plasma was slower than was that of ISIS-3082. ISIS-3082 distributes mainly to liver and kidney. Conjugation to cholesterol (ISIS-8005) or to  $C_{18}$  amine (ISIS-9047) increased substantially the fraction of the dose accumulated by the liver. Both also had a somewhat longer retention in plasma than ISIS-3082. However, neither lipophilic conjugate had an effect on metabolite patterns in plasma, liver, or kidney compared to ISIS-3082.

As a model to relative protein binding to human serum albumin, binding constants to bovin serum albumin (BSA) were measured. Binding to serum proteins plays a key role in the pharmacokinetics of oligonucleotides and, in view of the effects of phosphorothioates on clotting and complement activation, their

## Oligonucleotide Conjugates

401

toxicological properties as well. As a model for protein binding to human serum albumin in plasma, binding constants to BSA were measured. Binding of ISIS-3082 to BSA was comparable to that observed for other phosphorothioate oligodeoxynucleotides (17). Binding was salt-dependent and, at physiological salt concentrations, the  $K_d$  was approximately 140  $\mu$ M. The affinities of the lipophilic conjugates, ISIS-8005 and ISIS-9047, were greater at physiological salt concentrations than the affinity of ISIS-3082. Experiments in which ISIS-3082, ISIS-9047, and ISIS-8005 were coinubated confirmed the lack of salt dependency of binding of the two analogs and the salt dependency of binding ISIS-3082 to BSA. These data and other data suggest that phosphorothioate linkages are necessary for binding to BSA under physiological conditions, and that increased lipophilicity, either throughout the molecule or at the 5'-terminus, increased binding at physiological salt concentrations. Thus, more lipophilic phosphorothioate-containing analogs may bind to more than one type of site in BSA or more tightly to the phosphorothioate site.

The differences in serum protein binding are reflected in the pharmacokinetics of the analogs. The 5'-cholesterol adduct (ISIS-8005) and the C<sub>18</sub> amine conjugate (ISIS-9047) both showed increased retention in plasma relative to ISIS-302. Both also increased the proportion of dose in the liver substantially compared to ISIS-3082. It is not clear whether this change is due to an active transport of the lipophilic conjugates into the liver or whether the effects observed were simply due to the changes in lipophilicity. However, there was no improvement in distribution to central nervous system.

Neither the 5'-cholesterol nor C<sub>18</sub> amine modification enhanced resistance to metabolism significantly compared to ISIS-3082 when oligonucleotide was analyzed after extraction from liver of treated mice. However, the 3'-cholesterol conjugate of ISIS 3082 (ISIS-9388) was much more stable than the 5'-conjugate. The 3'-hydroxyl group, which is involved in the nucleophilic attack of the adjacent phosphate bond when the exonuclease enzyme makes a complex with the nucleic acid, is unavailable in ISIS-9388.

The 3'-cholesterol analog (ISIS-9388) was evaluated for its binding to lipoproteins and its biodistribution (18). ISIS-9388 associated with lipoproteins and had an altered metabolic fate compared with the nonconjugated phosphorothioate oligonucleotide ISIS-3082. The lipoprotein-associated oligonucleotide is not rapidly filtered by the kidneys and probably does not leak as rapidly in peripheral tissues as the underivatized oligonucleotide. As a result, ISIS-9388 circulates longer, which allows a longer exposure to its target.

## 5. In Vivo Therapeutic Efficacy of Cholesterol-Conjugated ICAM-1 Oligonucleotides

The greater concentration in liver was correlated with the therapeutic effect of the ISIS-8005 as measured by ICAM-1 mRNA levels in mouse liver *in vivo*. In

Manoharan

400




Figure 5 Isis lipophilic conjugates described in Table 1.

lipopolysaccharide-induced expression of ICAM-1 mRNA by intravenous treatment of the mouse with ISIS 8005 at a dose of 10 mg/kg 24 h and 2 h prior to polysaccharide treatment, improved efficacy of the drug was observed presumably due to cholesterol conjugation, as indicated by mouse ICAM-1 RNA levels in the liver. At this concentration, the unmodified oligonucleotide ISIS-3082 does not have any effect.

#### 6. Evaluation of Cholesterol-Conjugated Antisense Oligonucleotides in Other Biological Targets

Following the methods used to synthesize 2'- and 3'-cholesterol-uridine conjugates (15,19), the chemistry was extended to other nucleosides (adenosine and cytosine) and antisense oligonucleotide conjugates for several disease targets were synthesized. Synthesis of these cholesterol nucleosides was carried out by condensing cholesterol chloroformate with 2'-O-alkylamine or 3'-O-alkylamine of the appropriate nucleoside. The 2'-O-alkylamines were derived from direct alkylation procedure (20).

The 3'-cholesterol conjugated cytosine CPG was incorporated into an Ha-ras antisense oligonucleotide ISIS-13748 (the conjugate is the analog of 2'-deoxy-oligonucleotide phosphorothioate ISIS-2570). This compound was evaluated to determine the effect of cholesterol conjugation on RNase H activity in a cell-free assay. The cholesterol conjugate did not affect the RNase H cleavage rates or the extent of cleavage of the target RNA (Lima and Crooke, unpublished results, Isis Pharmaceuticals).

Activity of cholesterol-conjugated 2'-deoxy and 2'-O-MOE gapmer phosphorothioate oligonucleotides targeted against PKC- $\alpha$  and C-*raf* mRNAs has been reported (21). ISIS-8006, the cholesterol conjugate, was as active as the phosphorothioate oligonucleotide, ISIS-5132, in the presence of cationic lipids. In cultured T24 cells, in the absence of cationic lipids, ISIS-8006 was able to inhibit C-*raf* kinase mRNA expression while ISIS-5132 was inactive at 5- $\mu$ M concentration. In the same experiment, cholesterol-conjugated ICAM-1 antisense oligonucleotide was inactive in inhibiting C-*raf* kinase, supporting an antisense mechanism of action.

Cholesterol analogs of an antisense oligonucleotide targeting PKC- $\alpha$  have also been evaluated. ISIS-3521 is a potent, selective inhibitor of PKC- $\alpha$  gene expression in cell culture, has been shown to inhibit tumor growth in mice (22), and is currently in Phase III clinical trials. Three cholesterol analogs listed in Table 2 were tested in A549 cells and in T24 cells at 10- $\mu$ M concentration without cationic lipids. The cholesterol analogs were able to reduce PKC- $\alpha$  mRNA levels in both cell lines while ISIS-3521 was inactive.

#### Oligonucleotide Conjugates

**Table 2** Human C-*raf*, PKC- $\alpha$  and H-*ras* Oligonucleotides and Gapmers and Their Cholesterol Conjugates

Compound	Sequence	Target	Chemistry
ISIS-2570	CCACACGACGGCGGCC	Human H- <i>ras</i>	2'-H/P=S
ISIS-13748	CCACACCGACGGCGGCC*	Human H- <i>ras</i>	2'-H/P=S with 3'-cholesterol
ISIS-5132	TCCCGCCTGTGACATGCATT	Human C- <i>raf</i>	2'-H/P=S
ISIS-8006	U*CCCGCCTGTGACATGCATT	Human C- <i>raf</i>	2'-H/P=S and 5'-cholesterol
ISIS-3521	GTT CTC GCT GGT GAG TTT CA	Human PKC- $\alpha$	2'-H/P=S
ISIS-8007	GUT CTC GCT GGT GAG TTT CA	Human PKC- $\alpha$	2'-H/P=S
ISIS-9520	U*GTT CTC GCT GGT GAG TTT CA	Human PKC- $\alpha$	2'-H/P=S and 5'-cholesterol
ISIS-12373	GTT CTC GCT GGT GAG TTT CA U*	Human PKC- $\alpha$	2'-H/P=S and 3'-cholesterol
ISIS-9531	GUU CUC GCT GGT GA GUU UCA U	Human PKC- $\alpha$	P=S gapmer; 2'-F in wings
ISIS-9533	GUU CUC GCT GGT GA GUU UCA U*	Human PKC- $\alpha$	P=S gapmer; 2'-F in wings and 3'-cholesterol

## 7. Effect of Cholesterol Conjugation: Reports from Other Laboratories

Inhibition of expression of the multidrug resistance-associated P-glycoprotein by phosphorothioate and 5' cholesterol-conjugated phosphorothioate antisense oligonucleotides has been reported (23). Multiple drug resistance (MDR) is a result of overexpression of the P-glycoprotein drug transporter, a product of the MDR1 gene, and is a significant problem in cancer therapeutics. It was shown that 2'-deoxy phosphorothioate antisense oligonucleotides reduce levels of MDR1 message, inhibit expression of P-glycoprotein, and affect drug uptake in MDR mouse 3T3 fibroblasts. An oligonucleotide (ISIS-5995) directed against a sequence overlapping the AUG start codon was effective in reducing MDR1 transcript and protein levels when used at submicromolar concentrations in conjunction with cationic lipids, whereas a scrambled control oligonucleotide (ISIS-10221) was ineffective. Substantial and specific antisense effects could also be attained with a 5' cholesterol conjugate of the ISIS-5995 sequence without the need for cationic lipids. The 5' cholesterol ISIS-5995, but the not 5' cholesterol ISIS-10221, reduced MDR1 message and P-glycoprotein levels by 50–60% when used at 1- $\mu$ M concentrations. In parallel, treatment with 5' cholesterol ISIS-5995 also enhanced cellular accumulation of rhodamine 123, a well-known substrate of the P-glycoprotein transporter. The effectiveness of the cholesterol-conjugated ISIS-5995 appears to be due to its rapid and increased cellular uptake as compared to unconjugated oligonucleotide, as indicated in flow cytometry and confocal microscopy studies.

The pharmacokinetics of cholesterol conjugated oligonucleotides with unconjugated phosphorothioate oligonucleotides in female mice has been reported also by the researchers at Genta. They also observed that conjugation of cholesterol to phosphorothioate oligonucleotides increased the plasma half-life (24). Sixty minutes after injection, the levels of 3'-cholesterol conjugates are 3.8 times higher than those of unconjugated oligonucleotide, while the levels of 5'- and 5',3'-cholesterol conjugated oligonucleotides are 7.4 times higher.

Cholesterol conjugation has also been studied by Iverson et al. (25). 5'-cholesteryl-conjugated phosphorothioate oligodeoxynucleotides with sequence complementary to the rat CYP2B1 mRNA were evaluated in adult male Sprague-Dawley rats for their pharmacokinetic properties and ability to modulate CYP2B1 expression in vivo. After intraperitoneal administration of  $^{32}$ S-labeled oligodeoxynucleotides, volume of distribution for the phosphorothioate was reduced to 33% for the 5'-cholesteryl-conjugate oligodeoxynucleotide and the elimination half-life was reduced 50% for the cholesteryl-modified oligodeoxynucleotide relative to unconjugated controls. Hexobarbital sleep times, a measure of CYP2B1 enzyme activity in vivo, increased nearly 30% in cholesterol oligodeoxynucleotide-treated animals.

## Oligonucleotide Conjugates

Alefelder et al. reported the introduction of 3'- and 5'-terminal phosphorothioates into oligonucleotides and their postsynthetic modification with  $\alpha$ -(bromoacetamido)-3-cholesterol and 2-(5'-nitropyrinyl)-3-cholesterol disulfide to give cholesterol conjugates (26). A similar approach was used by Zhang et al. based on a phosphoramidite intermediate (27). The phosphorothioate derivatives with cholesterol at the 3'-end exhibit potent anti-HCMV activity, enhanced nuclease resistance and cellular association. An H-phosphonothioate solid-phase synthesis method facilitated the synthesis of oligonucleotide conjugates, as demonstrated by the example of attachment of 5'-cholesterol oligonucleotides to phosphorothioates (28). Acetal-mediated cholesterol conjugation has been reported by Pfeiderer's group (29). The 5'-O- or 2'-O-position of appropriately protected thymidine or uridine was subjected to acid-catalyzed reaction with cholesterylvinylether (29). The corresponding cholesteryl-acetals were derivatized to the phosphoramidites or succinates attached to polystyrene as solid support.

The effects of conjugating cholesterol to either or both ends of a phosphorothioate oligonucleotide were analyzed in terms of cellular uptake and antisense efficacy against the p75 nerve growth factor receptor (p75) in differentiated PC12 cells, which express high levels of this protein (30). The addition of a single cholesteryl group to the 5' end significantly increased cellular uptake and improved p75 mRNA down-regulation compared with the unmodified oligonucleotide. The 3'-cholesterol analog was more active still. Bis-cholesteryl (5'- and 3'-) conjugated oligonucleotide was even more potent and at 1  $\mu$ M as effective as high concentrations of cycloheximide at decreasing synthesis of p75. Inhibitory effects on the multiplication of mouse hepatitis virus by cholesterol-modified oligonucleotides complementary to the leader RNA have also been reported (31).

Cellular uptake of 3'-cholesterol-conjugated oligonucleotides has been examined with a real-time confocal laser microscopy (32). Cytosolic uptake of cholesterol conjugate was five times as rapid as that of phosphorothioate oligonucleotides and nuclear uptake of cholesterol conjugate was twice as fast as that of unmodified oligonucleotide. In this study, oligonucleotides were also labeled with 5'-fluorescein and the effect of fluorescein on uptake has not been separated from the effect of cholesterol.

Inhibition of transactivation of human immunodeficiency virus type-1 (HIV-1)-LTR by cholesterol-conjugated antisense oligonucleotides was compared to that of their unconjugated analogs in vitro (33) to study the efficiency of antisense oligonucleotides in inhibiting LTR-(HIV-1)-directed CAT expression catalyzed by tat protein. Antisense oligonucleotides modified by conjugation of cholesterol at the 3' end have a severalfold higher inhibitory response, and the inhibition by antisense oligonucleotides is sequence-specific.

In addition to effects on cellular uptake, cholesterol modulates oligonucleotide-mRNA hybrid stability via hydrophobic interactions (34). Two series of 3'-cholesterol- and/or 5'-cholesterol-conjugated oligonucleotides have been synthe-



ized. In the first group of compounds, the cholesteryl group was tethered at opposite ends of two oligonucleotides complementary to adjacent regions on the target. The cholesterol groups were adjacent to each other when the oligonucleotides were hybridized. When both oligonucleotides were hybridized to complementary RNA, an increase in the  $T_m$  of up to 13.3°C was observed in comparison to the  $T_m$  of two unmodified oligonucleotides of the same sequence. The authors observed a higher level of mismatch discrimination when the two adjacent cholesterol conjugates were compared to one continuous oligomer of the same overall length. The second set of compounds were 5'-3'-bis-cholesterol-containing oligonucleotides capable of forming "clamp-shaped" triple-stranded complexes, where cholesterol groups were attached to the termini of duplex- and triplex-forming domains. Stabilization of triplexes by up to 30° due to intercholesterol interaction was observed. The authors detected no triplex formation with a mismatched target. These data suggest that significant stabilization of complexes of nucleic acids could be achieved through intercholesterol hydrophobic interaction.

LeDoan et al. reported on interactions of phosphodiester oligonucleotides with the sequence of Hybridon GEM-91) linked to the cholesterol group at internal position (3, 7, or 22 positions of cholesterol) (35). The conjugates were assessed for their capacity to bind, penetrate, and partition in the cytoplasmic compartment of murine macrophages. The results showed that lipophilic conjugates bind to cells much faster ( $t_{1/2} \leq 10$  min) than do underivatized oligonucleotides. The fraction of oligomers that can freely diffuse from the cytosol was comparable for the phosphorothioate GEM-91 and for phosphodiester with cholesterol conjugated at position 7 (50–60% of the internalized oligomers), while the fraction of phosphodiester with cholesterol conjugated at position 3 was less (30% of internalized oligomers). The cytosolic fraction of internalized oligomers was studied by membrane permeabilization with digitonin. Membrane binding and internalization correlated well with the hydrophobicity of the conjugates, as characterized by their partition coefficients in a water-octanol system. However, pharmacological end points are provided.

Srinivasan et al. (36) evaluated interactions of deoxyphosphorothioate and cholesterol-conjugated oligonucleotides with BSA and human serum albumin (HSA) in vitro. The equilibrium dissociation constant  $K_m$  for the binding of the conjugates with BSA and HSA range between  $1.1$  and  $5.2 \times 10^{-5}$  and  $2.4$  and  $3.1 \times 10^{-4}$  M, respectively. HSA or BSA linked to Sepharose was incubated with 20-, or 24-mer phosphorothioates and selected drugs known to be highly protein bound (nifedipine, warfarin, midazolam, probenecid, indomethacin, and toxanthrone) were added. Up to 30% of S-ODN was displaced by warfarin in competition binding assays. Conversely, when HSA-bound warfarin was incubated with a variety of oligonucleotides, a 5'-cholesterol-conjugated 20-mer phosphorothioate displaced warfarin to a greater extent than unconjugated oligonucleotide. This experiment explains, in an indirect way, observations that cholesterol-conjugated oligonucleotides have longer plasma circulation than unmodified oligonucleotides.

### Mechanism of Action of Cholesterol-Conjugated Oligonucleotides

The mechanism of action of cholesterol-conjugated oligonucleotides in uptake enhancement and hence improving the efficacy has not been clearly established, although a receptor-mediated process involving lipoproteins has been implicated (12,13). Second, the lipophilicity of the hydrophobic steroid skeleton of cholesterol may be optimum to enhance cellular association. Third, cholesterol conjugates may form micellar structures that facilitate the transport of the conjugate within the cell. More mechanistic studies are needed to establish the exact mode of action.

### Toxicity of Cholesterol Conjugates and Other Lipophilic Conjugates

The toxicological properties of 2'-deoxyphosphorothioate ISIS-3082 and cholesterol analogs ISIS-9047 and ISIS-8005 (Fig. 5) were examined in Balb/c mice (37). Oligonucleotides were administered at a high dose of 50 mg/kg by i.v. bolus injection into the tail vein every other day for 14 days. In general, the properties exhibited for ISIS-3082 and the analogs were similar. Mice treated with ISIS-3082 were observed to have increases in liver transaminases and a decrease in triglycerides consistent with results from previous studies performed in CD-1 mice. Spleen weights were also increased in ISIS-3082-treated mice, but no histopathological alterations were noted. Alterations induced by ISIS-9047 and ISIS-8005 were qualitatively similar to those seen after treatment with ISIS-3082, but in general were more pronounced. Greater reductions in cholesterol and platelet counts and increases in blood urea nitrogen were observed relative to ISIS-3082. Red blood cell (RBC) counts and hematocrit were also reduced in mice treated with ISIS-9047 and ISIS-8005 relative to the ISIS-3082 treatment group. Kupffer cell hypertrophy and basophilic inclusions in Kupffer cells were observed in mice treated with ISIS-9047 and ISIS-8005, but not in ISIS-3082-treated mice. Iverson (25) observed some toxicity in his CYP12 study with cholesterol conjugates and ascribed them to the linkers used.

In a different study, a 20-mg/kg dose of ISIS-122726, a 2'-O-MOE gapmer oligonucleotide phosphorothioate with 3'-cholesterol, was administered to mice and biodistribution and toxicity were evaluated after 24 h. No visible signs of toxicity were observed. This dose is lower than that reported by Henry et al. (37) and also involves a different chemistry (M. Butler, unpublished results). Nevertheless, it is an encouraging finding to further evaluate cholesterol conjugates for in vivo applications.

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**